ClinicalTrials.gg
CompletedNCT00263653Updated Sep 21, 2016

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

A Phase 3 interventional study of Haemophilus influenzae type b- and meningococcal (vaccine) in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 16 sites in Spain. Open to participants aged 13 Months to 14 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
13 Months to 14 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
54th of 80
297 · median 445
Started
2005
with 6 others
Phase 3
48 of 82
none open now
Registered
11th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 54th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2005, is one of 48 in phase 3, and was the 11th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 13 Months to 14 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of the candidate Hib-MenC conjugate vaccine given concomitantly with measles, mumps and rubella (MMR) vaccine, versus Hib-MenC only and MMR only, when given to healthy subjects aged 13 to 14 months who were primed with 3 doses of Hib (as part of a DTPa -containing vaccine) and MenC-CRM197.

Read the detailed description

This multicenter study is open with respect to the treatment allocation, but double-blind with respect to the Hib-MenC-TT lots (3 lots). Hib-MenC-TT and Priorix™, when given separately, serve as active controls. Two blood samples are taken: before and one month after vaccination. Additional vaccines are offered at study end in order to complete the vaccine schedule recommended in Spain

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis
04

Who can participate

Ages eligible
13 Months to 14 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female between, and including, 13 and 14 months of age.
  • Previously completed 3-dose primary vaccination with a MenC-CRM197 vaccine, and Hib (given as part of a combined DTPa-containing vaccine) with at least 6 months between the administration of the third doses and the study entry.

Exclusion criteria

Exclusion criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the study vaccine, or planned use during the study period.
  • Previous vaccination against OR history of H. influenzae type b (Hib) and/or meningococcal serogroup C disease and/or measles, mumps or rubella OR known exposure to measles, mumps or rubella within 30 days prior to the start of the present study.
  • Any confirmed or suspected or immunodeficient condition, including (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of any neurologic disorders or seizures.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine including neomycine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
297 participants (actual)

Interventions

  • BiologicalHaemophilus influenzae type b- and meningococcal (vaccine)
06

What researchers measure

Primary outcomes

  1. Any grade 3 solicited symptoms (d 0 - 3)

Secondary outcomes

  1. Sol (d 0-3, local & general), unsol & MMR specific (d 0-42) symptoms. SAEs (whole study). Subjects with Hib-MenC (pre&42 d post vacc): SBA-MenC titers, anti-PRP, -PSC conc. Subjects with MMR (42 d post vacc): anti-measles, -mumps, -rubella seroconversion

07

Study locations

16 sites
  • GSK Investigational Site
    Almería, 04007, Spain
  • GSK Investigational Site
    Almería, 04009, Spain
  • GSK Investigational Site
    Antequera/Málaga, 29200, Spain
  • GSK Investigational Site
    Aravaca, 28023, Spain
  • GSK Investigational Site
    Blanes, Spain
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Lérida, 25006, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28035, Spain
  • GSK Investigational Site
    Marbella, 29600, Spain
  • GSK Investigational Site
    Mollet del Valles/Barcelona, 08100, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Sant Adriá de Beyós, Barcelona, 08930, Spain
  • GSK Investigational Site
    Sant Eugenia de Berga, Barcelona, 08519, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Velez, Malaga, Spain
08

References and documents

Publications

  • Carmona A, Miranda M, Barrio F, De Vicente A, Mares J, Munoz E, Diez-Delgado J, Alonso A, Gimenez-Sanchez F, Merino J, Garcia-Corbeira P, Maechler G, Boutriau D; Spanish 103954 Study Group. Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine. Pediatr Infect Dis J. 2010 Mar;29(3):269-71. doi: 10.1097/INF.0b013e3181c15977. PubMed 19952860 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Mar 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2005
First posted
Dec 9, 2005
Start
Mar 2005
Primary completionActual
Mar 2005
CompletionActual
Sep 2005
Last update
Sep 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00263653
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 9, 2005
Start date
Mar 2005
Primary completion
Mar 2005
Completion
Sep 2005
Last update
Sep 21, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion